Revive Therapeutics Ltd. (31R.F)

0.0100 0.0000 (0.00%) 市場開市。 截至 08:18AM CEST。

Revive Therapeutics Ltd.

The Canadian Venture Building
82 Richmond Street East
Toronto, ON M5C 1P1
Canada
888-901-0036
https://revivethera.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Michael Frank	Chairman & CEO	244.02k	無	1961
Mr. Carmelo Marrelli ACIS, B.Comm., C.A., CGA, CPA	Chief Financial Officer	88.19k	無	1971
Dr. Kelly T. McKee Jr., M.D., M.P.H.	Chief Scientific Officer Consultant	無	無	1951
Dr. Onesmo Mpanju Ph.D.	Chief Regulatory Affairs Consultant	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. The company is based in Toronto, Canada.

公司管治

截至 無 止，Revive Therapeutics Ltd. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。